PURE Bioscience Reports Fiscal First Quarter 2021 Financial Results

RANCHO CUCAMONGA, Calif.--(BUSINESS WIRE)--PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal first quarter ended October 31, 2020. Summary of Results – Fiscal First Quarter Operations Net product sales for the fiscal first quarter ended October 31, 2020 increased 256% to 1,417,000, compared to $398,000 for the fiscal first quarter ended October 31, 2019. The increase of $1,019,000

Click to view original post